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Abstract 
PARK2 (also known as Parkin RBR E3 ubiquitin 
protein ligase) is one of the largest genes in our 
genome. It undergoes an extensive alternative 
splicing both at transcript and protein level, 
producing multiple transcript variants and distinct 
protein isoforms. The precise function of PARK2 is 
still not clear; however, the encoded protein is a 
component of a multiprotein E3 ubiquitin ligase 
complex that mediates the targeting of substrates for 
proteasomal degradation. Mutations in this gene 
cause Parkinson disease and autosomal recessive 
juvenile Parkinson disease. Further molecular 
defects have been linked to other human 
malignancies. Here, we review some major data on 
PARK2, concerning the genetic structure, the 
transcription regulation, the encoded protein and 
functions, and its implication in human diseases. 
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Identity 
Other names: PARK2, PDJ, PRKN, AR-JP, 
LPRS2, Parkin 
HGNC (Hugo): PRKN 
Location: 6q26 
Local order: PARK2 is flanked towards the 
telomeric direction by PACRG (or PARK2 co-
regulated) gene, which lies in a head-to-head 
arrangement and shares a common promoter with the 
adjacent PARK2 (West et al., 2003). In the 
centromeric direction PARK2 is flanked by 
AGPAT4 (1-acylglycerol-3-phosphate O-
acyltransferase), which encodes a member of the 1-
acylglycerol-3-phosphate O-acyltransferase family. 
According to NCBI MapViewer, further elements 
overlap or surround the PARK2 genetic region, such 
as two pseudogenes (KRT8P44 and TRE-TTC15-1) 
and a set of non-coding RNAs (LOC105378094, 
LOC105378098, LOC105378097 and 
LOC105369171). 
Figure 1 displays the human chromosome 6 (NCBI Reference Sequence NC_000006.12) and relative localization and orientation 
of PARK2 and flanking genes. PARK2 gene is represented in blue and is transcribed in antisense orientation (reverse strand). 
Further genes and non-coding RNAs map in this locus. 
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Figure 2 displays the three full-length Reference Sequences of PARK2 gene (NCBI - Nucleotide Database). Corresponding 
GenBank Accession Numbers are indicated on the left. Exons are represented as coloured boxes (blue for coding regions and 
grey for non coding), whereas the dashed line indicates intronic regions. The green triangle specifies the start codon, while the 
red one designates the stop codon. 
 
DNA/RNA 
Description 
PARK2 is one of the largest genes in the human 
genome, and spans more than 1.38 Mb of genomic 
DNA in the long arm of chromosome 6 (reverse 
strand). Based on the first isolated transcript, the 
genomic organization and exon/intron boundary 
sequences of PARK2 were established of 12 exons. 
Transcription 
Currently, the NCBI RefSeq database annotates 3 
representative transcripts as full-length PARK2 
mRNAs (Figure 2). However, Homo sapiens cDNA 
sequences deposited in GenBank and UniGene 
repositories, coaligned on the genomic sequence and 
clustered in a minimal non-redundant way, support 
at least 21 different alternatively spliced mRNAs 
composed by 17 exons (Figure 3) (La Cognata et al., 
2014; Scuderi et al., 2014). Each of these splice 
variants is indicated in Table 1. 
Pseudogene 
No known pseudogenes. 
Protein 
Description 
The canonical PARK2 protein (Accession number 
BAA25751.1) (465 aa) comprises an N-terminal 
ubiquitin-like (UBQ) domain and two C-terminal in-
between ring fingers (IBR) domains (Kitada et al., 
1998).  
 
Domain Start Stop E-value  
UBQ 1 72 2.95e-16 
IBR 313 377 4.49e-14 
IBR 401 457 0.142 
 
The UBQ domain targets specific protein substrates 
for degradation by the proteasome, whereas IBR 
domains occur between pairs of ring fingers and play 
a role in protein quality control (Figure 4). The 
predicted PARK2 protein isoforms, encoded by the 
alternative splice transcripts currently known, 
structurally diverge from the canonic one for the 
presence or absence of the UBQ domain and for one 
or both IBR domains. Moreover, when UBQ domain 
is present, it often differs in length from the 
canonical one (La Cognata et al, 2014: Scuderi et al., 
2014). 
Expression 
PARK2 is widely expressed in a variety of tissue  
types, including nervous system areas (brain, 
substantia nigra, mesencephalon, cerebellum, frontal 
cortex, striatum) (Shimura et al., 2001; 
Schlossmacher et al., 2002; LaVoie et al., 2005; Sun 
et al., 2013) and peripheral regions (skeletal muscle, 
heart and testicular tissue) (Kitada et al., 1998; 
Rosen et al., 2006), as well as in immortalized cell 
lines (neuroblastoma, kidney, epithelial, breast 
cancer and colon cancer cell lines) (Yamamoto et al., 
2005; Henn et al., 2007; Poulogiannis et al., 2010; 
Tay et al., 2010).  
Gene #mRNA Acc.Num. Transcript Length 
PARK2  
1. NM_004562.2 4073 bp 
2. AF381282.1 1157 bp 
3. AF381284.1 1158 bp 
4. BC022014.2 1575 bp 
5. NM_013987.2 3989 bp 
6. NM_013988.2 3626 bp 
7. AK294684.1 1115 bp 
8. GU345837.1 1298 bp 
9. GU345838.1 1340 bp 
10. GU345840.1 1313 bp 
11. GU357501.1 936 bp 
12. GU357502.1 873 bp 
13. GU361466.1 1279 bp 
14. GU361467.1 1229 bp 
15. GU361468.1 1010 bp 
16. GU361469.1 1559 bp 
17. GU361470.1 1561 bp 
18. GU361471.1 634 bp 
19. KC357594.1 454 bp 
20. KC357595.1 1627 bp 
21. KC774171.1 1282 bp 
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Figure 3 displays the structures of the currently known PARK2 mRNA splicing variants listed in Unigene Cluster Hs.132954 (La 
Cognata et al., 2014). Each mRNA variant is indicated with a number corresponding to that indicated in the Table 1. 
 
 
Figure 4 shows the domain composition of PARK2 protein, obtained from SMART Genome tool (http://smart.embl.de/). UBQ is 
the N-term ubiquitin domain, while IBRs are the C-term in-between ring fingers domains. In Table 2 are reported the aminoacidic 
start and stop positions and the E-value of the domain prediction. 
 
 
Figure 5 (adapted from Scuderi et al., 2014) shows a representative immunoblot of parkin protein isoforms in homogenized rat 
brain, visualized by using five different antibodies (Ab1, Ab2, Ab3, Ab4, Ab5). Immunoblot for β-tubulin is used as control. The 
right panel of the figure shows the localization of the epitopes recognized by the five antibodies on the canonical parkin protein. 
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Figure 6 (adapted from Maugeri et al., 2015) shows the immunolocalization of parkin protein in glioblastoma cell lines (A172 
cells). β-actin (red) was used as control and nuclei were stained with DAPI (blue). 
 
In addition, distinct expression patterns of the 
PARK2 spliced isoforms have emerged in human 
leukocytes (Kasap et al., 2009), glioma and lung 
adenocarcinoma cell lines (D'Amico et al., 2015; 
Maugeri et al., 2015) and aged brain (Pawlyk et al., 
2003). The differential expression of PARK2 splice 
isoforms have also observed in rat and mouse central 
and peripheral tissues and developmental stages 
(Horowitz et al., 1999; D'Agata et al., 2000; Gu et 
al., 2000; Stichel et al., 2000; Huynh et al., 2001). 
Localisation 
Subcellular localisation: PARK2 is mainly 
cytoplasmatic (Figure 5). Positive signals have been 
detected in endoplasmic reticulum (Imai et al., 
2002), perinuclear region, microtubules (Ren et al., 
2003), nucleus and plasma membrane. PARK2 
protein also colocalizes with Lewy bodies 
(Schlossmacher et al., 2002), the pathological 
hallmark of Parkinson's Disease and dementia. 
Function 
PARK2 protein acts as an E3 ubiquitin protein ligase 
and is responsible of substrates recognition for 
proteasome-mediated degradation. It tags various 
types of proteins, including cytosolic (SNCAIP 
(Synphilin-1), GPR37 (Pael-R), SEPT5  
(CDCrel-1) and 2a, SNCA ID: 46121> (α-
synuclein), p22, Synaptogamina XI) (Imai et al., 
2000; Shimura et al., 2000; Zhang et al., 2000; 
Chung et al., 2001; Staropoli et al., 2003), nuclear 
(Cyclin E, Cyclin D) (Ikeuchi et al., 2009; Gong et 
al., 2014) and mitochondrial ones (MFN1 and 
MFN2, VDAC, TOMM70A, TOMM40 and 
TOMM0, BAK1, RHOT1 (MIRO1) and RHOT2 
(MIRO2), FIS1) (Narendra et al., 2008; Chan et al., 
2011; Yoshii et al., 2011; Cookson, 2012; Jin et al., 
2012).  
The number of targets is such high that parkin 
protein results involved in numerous molecular 
pathways (proteasome-degradation, mitochondrial 
homeostasis, mitophagy, mitochondrial DNA 
stability, regulation of cellular cycle). 
Homology 
PARK2 gene shows a great evolutionary 
conservation across species, especially mammals. 
Mouse and rat species represent the most common 
animals used to model and study human pathologies.  
Human PARK2 protein shows a protein similarity of 
about 50% with rat, while it is more similar with the 
mouse parkin (90% of similarity) (protein similarity 
is calculated used Genomicus - PhyloView tool) 
(Figure 8). 
 
Figure 7 shows the major pathways in which PARK2 protein is involved: proteasome-degradation of substrates, mitochondrial 
homeostasis and mitophagy, and regulation of cellular cycle and cell death. 
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Figure 8 shows the evolutionary PARK2 Gene Tree, constructed using the multiple genome comparison tool PhyloView of 
Genomicus v.82.01 (http://www.genomicus.biologie.ens.fr/). This tool compares a specific gene with all the genomes that 
possess a homolog (Louis et al., 2015). Mammalia taxon has been defined as the root of the tree. PARK2 gene is displayed and 
highlighted in the central part of the figure. The internal nodes of the phylogenetic tree are represented as red boxes for 
duplication and blue boxes for speciation events. The percentage of similarity of homologous proteins is represented with 
different colours, as indicated in the legend. 
 
Mutations 
Germinal 
A wide spectrum of loss-of-function mutations in 
PARK2 including simple mutations (nonsense, 
missense and splice site mutations), frameshift 
indels or in the untraslated regions, as well as Copy 
Number Variations of the promoter region and single 
or multiple exons PARK2 mutations, were identified 
across the entire gene in either homozygous, 
compound heterozygous or heterozygous state in 
familial and sporadic patients from different 
ethnicities. Heterozygous PARK2 variants have also 
been observed in healthy control individuals, making 
the assessment of pathogenicity for these variants 
quite complex. A complete and updated view of all 
PARK2 currently known mutations is available at 
the Parkinson Disease Mutation Database 
(http://www.molgen.vib-ua.be/PDMutDB/), which 
collects DNA variations screened among more than 
800 families and linked to PD. 
Somatic 
Along with the germinal mutations occuring in 
Parkinson's Disease, genetic defects have also been 
observed in solid tumors. Based on the analysis of 
recent next generation sequencing data, the 
frequency of PARK2 mutations is relatively high in 
cervical cancer (5.6 %), lung squamous cell cancer 
(5.6 %), colorectal cancer (2.4 ~ 5.6 %), gastric 
cancer (4.6 %), skin cutaneous melanoma (3.5 %), 
lung adenocarcinoma (2.7 ~ 3.1 %), and 
endometrioid cancer (2.1%) Most cancer-derived 
PARK2 mutations are located at conserved regions, 
and more than 10% of mutations lead to frame shifts 
or truncations, suggesting that those mutations may 
disrupt or abolish the function of PARK2 (Xu et al., 
2014). A list of the known cancer-derived mutations 
is available at the COSMIC Database and is 
summarized in Figure 9. 
Mutation Type Mutant samples 
Substitution nonsense 6 
Substitution missense 105 
Substitution synonymous 52 
Insertion inframe 0 
Insertion frameshift 2 
Deletion inframe 0 
Deletion frameshift 4 
Complex 1 
Other 0 
Epigenetics 
Promoter hypermethylation is a common epigenetic 
mechanism to alter the gene expression. PARK2 
promoter hypermethylation has been found in acute 
lymphoblastic leukemia, chronic myeloid leukemia 
and colorectal cancer (Agirre et al., 2006; Xu et al., 
2014). However, the pathogenic role of specific 
epigenetic changes has not been yet clarified. 
Implicated in 
Parkinson's Disease 
Note 
Mutations in PARK2 are responsible of 50% of cases 
with autosomal recessive juvenile Parkinsonism 
(AR-JP). They also explain ~15% of the sporadic 
cases with onset before 45 (Lucking et al., 2000; 
Bonifati, 2012) and act as susceptibility alleles for 
late-onset forms of Parkinson disease (2% of cases) 
(Oliveira et al., 2003).  
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Figure 9 shows the overall distribution of PARK2 somatic mutations in cancer listed in COSMIC Database 
(http://cancer.sanger.ac.uk/cosmic) (November 2015). The exact number of collected somatic mutations in different cancer types 
is indicated in Table 3. 
 
Clinical features of PARK2 homozygous mutation 
carriers are generally indistinguishable from those of 
idiopathic PD patients with the exception of a clear 
drop in onset age. Typically PARK2 patients present 
the classic symptoms of PD (such as bradykinesia, 
rigidity, and tremor), disease onset before the age of 
50 years and a slow disease progression. Although 
they respond well to levodopa treatment, they are 
more likely to develop treatment-induced motor 
complications earlier in the treatment (Nuytemans et 
al., 2010). 
Alzheimer Disease 
Lonskaya and colleagues investigated the role of 
parkin in postmortem brain tissues from 21 patients 
with Alzheimer Disease (AD) and 15 control 
subjects. They observed decreased parkin solubility 
in cortex of patients and parkin co-localization with 
intraneuronal amyloid-beta depositions (Aβ1-42) in 
the hippocampus and cortex. Parkin accumulation 
with intraneuronal Aβ and p-Tau was detected in 
autophagosomes in AD brains. By using a gene 
transfer animal model, the authors also demonstrated 
that the expression of wild type parkin facilitate 
autophagic clearance and promoted deposition of 
Aβ1-42 and p-Tau into the lysosome (Lonskaya et 
al., 2013). Parkin, therefore, may clear autophagic 
defects via autophagosome degradation. 
Leprosy 
Using a positional cloning strategy in 197 
Vietnamese leprosy simplex families, Mira et al. 
found significant associations between leprosy and 
17 markers in the 5-prime regulatory region shared 
by PARK2 and PACRG. They then confirmed these 
results in 587 Brazilian leprosy cases and 388 
unaffected controls. RT-PCR analysis detected wide 
expression of both PARK2 and PACRG in tissues, 
and suggested that, in addition to the common 
bidirectional promoter, gene-specific  
transcriptional activators may be involved in 
regulating cell- and tissue-specific gene expression 
(Mira et al., 2004). In 2013, Alter et al. replicated 
these findings showing a susceptibility locus in the 
shared PARK2 and PACRG promoter region in a 
Vietnamese population.  
They also found that two SNPs (rs1333955 and 
rs2023004) were associated with susceptibility to 
leprosy in a northern Indian population (Alter et al., 
2013). 
Gliomas 
Veeriah et al. provided evidence that PARK2 acts as 
a tumour suppressor gene in glioblastoma 
multiforme. Genetically, they detected PARK2 copy 
number loss in 53 of 216 glioblastomas and somatic 
point mutations in 7 glioblastomas specimens 
(Veeriah et al., 2010). The action of tumour 
suppressor gene for gliomas has been furthermore 
described by Yeo et al., who found parkin expression 
dramatically reduced in glioma cells, while its 
restoration promoted G(1) phase cell-cycle arrest 
and mitigated the proliferation rate (Yeo et al., 
2012). Authors suggested the analysis of parkin 
pathway activation as predictive for the survival 
outcome of patients with glioma. The effects of 
PARK2 on tumour cell growth were also confirmed 
by Lin et al., who reported that PARK2 is frequently 
deleted and underexpressed in human gliomas, and 
that restoration of PARK2 significantly inhibited 
glioma cell growth (Lin et al., 2015).  
An interesting transcriptional target of parkin is p53. 
Viotti et al. were able to demonstrate that parkin 
levels inversely correlate to brain tumour grade and 
p53 levels in oligodendrogliomas, mixed gliomas 
and glioblastomas, and established that p53 controls 
parkin promoter transactivation, mRNA and protein 
levels (Viotti et al., 2014). 
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Figure 10 (adapted from Ambroziak et al., 2015) shows the hypothesized mechanism of the Ex2-5 duplication observed in a 
patient with early-onset PD. The authors suggest the FoSTeS/MMBIR (fork stalling and template switching/micro-homology-
mediated break-induced replication) mechanism as responsible of the rearrangement. Upon replicating, the first exon of the 
PARK2 gene replication fork stalled and one strand invaded either the sister molecule or the homologue chromosome in inverted 
orientation (1), resulting in inverted duplication. Subsequently, the original forks were restored, but primed upstream of the point 
where it first stalled (2), leading to the triplication of the red-highlighted region (Ambroziak et al., 2015). 
 
Colon cancer 
Microarray analysis revealed copy number loss in 24 
of 98 colon cancers and different PARK2 somatic 
point mutations in 2 colon cancer cells lines (Veeriah 
et al., 2010). Additionally, in 100 primary colorectal 
carcinomas, Poulogiannis et al. demonstrated by 
array comparative genomic hybridization that 33% 
show PARK2 copy number loss (Poulogiannis et al., 
2010). The PARK2 deletions are mostly focal, 
heterozygous, and show maximum incidence in 
exons 3 and 4. Deficiency in expression of PARK2 
is significantly associated also with adenomatous 
polyposis coli (APC) deficiency in human colorectal 
cancer. Moreover, in the same study, interbreeding 
of Park2 heterozygous knockout mice with 
Apc(Min) mice resulted in a dramatic acceleration of 
intestinal adenoma development and increased polyp 
multiplicity. 
Lung adenocarcinoma 
Somatic homozygous deletions of exon 2 of the 
PARK2 gene were found in 2 lung adenocarcinoma 
cell lines, Calu-3 and H-1573, suggesting that the 
loss of this locus and the resulting changes in its 
expression are involved in the development of the 
tumour (Cesari et al., 2003). Additional germline and 
somatic deletions were also reported by Iwakawa et 
al. in five patients with lung adenocarcinoma and in 
31/267 lung adenocarcinoma, indicating that somatic 
PARK2 mutations occur rarely in lung 
adenocarcinoma development, but germline 
mutations could contribute to tumour progression 
(Iwakawa et al., 2012). Very recently, Xiong et al. 
reported the PARK2 germline mutation c.823C>T 
(p.Arg275Trp) in a family with eight cases of 
lung cancer (Xiong et al., 2015). 
Ovarian Cancer 
Two different groups identified both PARK2 genetic 
alterations and downregulated expression in ovarian 
cancer. Cesari et al. detected two PARK2 truncating 
deletions in 3 of 20 ovarian tumour samples, 
supporting the hypothesis that hemizygous or 
homozygous deletions are responsible for the 
abnormal expression of PARK2 in tumour biopsies 
and tumour cell lines. They suggest that PARK2 may 
act as a tumour suppressor gene and may contribute 
to the initiation and/or progression of ovarian cancer 
(Cesari et al., 2003). Denison et al. found four cell 
lines and four primary tumours as heterozygous for 
the duplication or deletion of a Parkin exon. The 
analysis of Parkin protein expression revealed that 
most of the ovarian cancer cell lines and primary 
tumours had diminished or absent Parkin expression 
(Denison et al., 2003). 
Other malignancies 
Alterations or molecular defects involving the 
coding region of the gene (single nucleotide 
mutations, copy numbers, gene breakage), 
epigenetic mechanisms, the mRNA up or down 
regulation, the protein level and the abnormal 
splicing of PARK2 have been linked to a wide range 
of other human malignancies (i.e. acute 
lymphoblastic leukemia, chronic myeloid leukemia, 
clear cell renal cell carcinoma, hepatocellular 
carcinoma, head and neck squamous cell carcinoma, 
gastric cancer, pancreatic adenocarcinoma, breast 
cancer, bladder urothelial cancer, thyroid cancer, 
adenoid cystic carcinoma) (Xu et al., 2014). 
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Breakpoints 
PARK2 belongs to the family of extremely large 
human genes and is located within FRA6E, one of 
the most unstable common fragile sites (CFSs) of the 
human genome. CFSs are intrinsically difficult to 
replicate, and are known to play a major role in 
carcinogenesis. Some factors have been considered 
to contribute to instabilities, including late-
replicating genomic regions, high AT content, 
flexible DNA sequences or regions enriched in 
repetitive elements. The exact size of the region of 
instability of FRA6E is not yet clear; however, it has 
been suggested that it may span even 9 Mb at 6q25.1-
6q26 and that the main fragility core is localised on 
the telomeric end, within the PARK2 gene sequence. 
The most common molecular mechanisms which 
seem predominantly involved in the rearrangement 
processes of this genomic region are non-
homologous end joining (NHEJ) and fork stalling 
and template switching (FoSTeS)/micro-homology 
mediated break-induced replication (MMBIR) 
(Figure 10) (Ambroziak et al., 2015). 
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